Results 11 to 20 of about 13,380 (189)

Eculizumab‐related drug reaction in a patient with neuromyelitis optica

open access: yesClinical Case Reports, 2023
Eculizumab is approved for treatment of antibody positive neuromyelitis optica, myasthenia gravis, and hematologic disorders like paroxysmal nocturnal hemoglobinuria. Drug rash has not yet been reported as a side effect of eculizumab. We report a case of
Rishi Sharma, Moises Romo, Flavia Nelson
doaj   +2 more sources

Treating C3 glomerulopathy with eculizumab

open access: yesBMC Nephrology, 2018
Background C3 glomerulopathy (C3G) is a rare, but severe glomerular disease with grim prognosis. The complex pathogenesis is just unfolding, and involves acquired as well as inherited dysregulation of the alternative pathway of the complement cascade ...
Thomas Welte   +7 more
doaj   +2 more sources

Eculizumab as Additional Rescue Therapy in Myasthenic Crisis

open access: yesMuscles
Eculizumab is a monoclonal antibody blocking the terminal complement protein C5. As demonstrated in the phase III randomized, placebo-controlled, REGAIN clinical trial, eculizumab is efficacious in acetylcholine receptor antibody (AChR-Ab)-positive ...
Francesco Crescenzo   +8 more
doaj   +2 more sources

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome [PDF]

open access: yesClinical Pharmacology: Advances and Applications, 2011
Maro Ohanian, Christian Cable, Kathleen HalkaDepartment of Hematology and Oncology, Scott and White Healthcare, The Texas A&M Health Science Center College of Medicine, Temple, TX, USAAbstract: This case report describes how eculizumab reversed ...
Ohanian M, Cable CC, Halka KK
doaj   +2 more sources

Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension [PDF]

open access: yes, 2021
Objective To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal ...
Muppidi, S   +999 more
core   +9 more sources

Eculizumab for Shiga‐toxin‐induced hemolytic uremic syndrome in adults with neurological involvement [PDF]

open access: yeseJHaem
The role of eculizumab in treating Shiga‐toxin‐producing Escherichia coli (STEC) hemolytic uremic syndrome (HUS) patients with neurological involvement remains unclear.
Benjamin J. Lee   +10 more
doaj   +2 more sources

Mapping of C5-Blocking Monoclonal Antibodies Reveals New C5 Inhibitory Epitopes and Novel Modes of C5 Inhibition. [PDF]

open access: yesImmunology
We identify four distinct C5 inhibitory epitopes, including two novel antibodies that selectively block membrane attack complex (MAC) assembly while preserving C5 cleavage and C5a generation. These findings establish selective MAC inhibition as a new therapeutic strategy for complement‐mediated diseases.
Cooke RS   +5 more
europepmc   +2 more sources

Eculizumab discontinuation in atypical haemolytic uraemic syndrome : TMA recurrence risk and renal outcomes [PDF]

open access: yes, 2021
Eculizumab modifies the course of disease in patients with atypical haemolytic uraemic syndrome (aHUS), but data evaluating whether eculizumab discontinuation is safe are limited.
Miller, Benjamin   +16 more
core   +1 more source

Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan

open access: yesTherapeutic Advances in Neurological Disorders, 2023
Background: The terminal complement C5 inhibitor eculizumab is approved in Japan for relapse prevention in aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) and is undergoing mandatory post-marketing surveillance (PMS ...
Ichiro Nakashima   +6 more
doaj   +1 more source

Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.

open access: yesPLoS ONE, 2020
IntroductionEculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk.
Catherine H Bozio   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy